DRG Epidemiology’s coverage of narcolepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of narcolepsy for each country, as well as annualized case counts projected to the national population.
Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years.
- Mature Markets Data
- Key Findings
- Prevalence of Narcolepsy per 100,000 Among People of All Ages in 2019 and 2039
- Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Narcolepsy over the Next 20 Years
- Epidemiology Data
- Epidemiology Populations
- Diagnosed Prevalence
- Diagnosed Incidence
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Alison Isherwood, MSc, MRes, PhD
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.